| Product Code: ETC6551476 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The large molecule drug substance CDMO import shipments to Bulgaria witnessed a significant increase in concentration levels in 2024, with top exporting countries being Italy, USA, Sweden, Germany, and UK. The Herfindahl-Hirschman Index (HHI) indicated very high concentration, reflecting a competitive landscape dominated by a few key players. Despite a remarkable compound annual growth rate (CAGR) of 20.01% from 2020 to 2024, the negative growth rate of -79.06% from 2023 to 2024 suggests a recent decline in import volumes, signaling potential shifts in Market Top 5 Importing Countries and Market Competition (HHI) Analysis dynamics or regulatory changes impacting the industry.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Bulgaria Large Molecule Drug Substance CDMO Market Overview |
3.1 Bulgaria Country Macro Economic Indicators |
3.2 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Bulgaria Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Bulgaria Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Bulgaria Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologics and large molecule drugs globally |
4.2.2 Growing trend towards outsourcing manufacturing services to specialized CDMOs |
4.2.3 Favorable government regulations and incentives supporting the pharmaceutical industry in Bulgaria |
4.3 Market Restraints |
4.3.1 Intense competition from established CDMOs in other regions |
4.3.2 Challenges in maintaining quality standards and compliance with regulatory requirements |
4.3.3 Limited capacity and scalability of existing facilities in Bulgaria |
5 Bulgaria Large Molecule Drug Substance CDMO Market Trends |
6 Bulgaria Large Molecule Drug Substance CDMO Market, By Types |
6.1 Bulgaria Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Bulgaria Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Bulgaria Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Bulgaria Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Bulgaria Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Bulgaria Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Bulgaria Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Bulgaria Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage of capacity utilization of large molecule drug substance manufacturing facilities in Bulgaria |
8.2 Number of new client partnerships secured by Bulgarian CDMOs |
8.3 Investment in research and development capabilities for large molecule drug substance production in Bulgaria |
9 Bulgaria Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Bulgaria Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Bulgaria Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Bulgaria Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Bulgaria Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Bulgaria Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Bulgaria Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |